The present report is the first to demonstrate the safety and efficacy of dual EGFR and ABL TKI treatment in a patient with concomitant EGFR-mutated lung adenocarcinoma and CML. Here, EGFR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.